Drugs in Dev. Gastroenterology
Phase I
United Kingdom 
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Oxilio
Deal Size : Undisclosed
Deal Type : Agreement
Details : Quotient has prior experience of working with the Nuformix NXP-001 co-crystal and previously developed a capsule and a powder for oral suspension formulation of Aprepitant, evaluating its performance in a relative bioavailability study versus EMEND.
Product Name : NXP-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 02, 2022
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Oxilio
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : VTP-1000
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Barinthus Initiates Phase 1 Trial of VTP-1000 for Celiac Disease
Details : VTP-1000 is an investigational, injectable antigen-specific tolerance immunotherapy that utilizes Barinthus Bio’s platform. Currently, it is being evaluated for the treatment of celiac disease.
Product Name : VTP-1000
Product Type : Vaccine
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : VTP-1000
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Quotient Sciences- Molecule to Cure. Fast.
